Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRA1D | P25100 | 1/20 | 0.69 |
| ▸ | PTAFR | P25105 | 1/20 | 0.69 |
| ▸ | HTR1D | P28221 | 1/20 | 0.69 |
| ▸ | HTR2C | P28335 | 1/20 | 0.69 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.69 |
| ▸ | DRD3 | P35462 | 1/20 | 0.69 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.69 |
| ▸ | FABP3 | P05413 | 1/20 | 0.58 |
| ▸ | PLA2G2C | Q5R387 | 1/20 | 0.53 |
| ▸ | MAPT | P10636 | 1/20 | 0.53 |
| ▸ | RECQL | P46063 | 1/20 | 0.51 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.50 |
| ▸ | PRKCG | P05129 | 1/20 | 0.50 |
| ▸ | PRKCB | P05771 | 1/20 | 0.50 |
| ▸ | PRKCA | P17252 | 1/20 | 0.50 |
| ▸ | PRKCH | P24723 | 1/20 | 0.50 |
| ▸ | AKT1 | P31749 | 1/20 | 0.50 |
| ▸ | PRKCI | P41743 | 1/20 | 0.50 |
| ▸ | PRKCE | Q02156 | 1/20 | 0.50 |
| ▸ | PRKCQ | Q04759 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4007176 | 1.00 | ADRA1D (0.69) | ADRA1DPTAFRHTR1DHTR2CADRA1B | |
| SCHEMBL2541438 | 0.94 | ADRA1D (0.77) | ADRA1DPTAFRHTR1DHTR2CADRA1B | |
| SCHEMBL26642985 | 0.94 | ADRA1D (0.77) | ADRA1DPTAFRHTR1DHTR2CADRA1B | |
| SCHEMBL26642897 | 0.94 | ADRA1D (0.77) | ADRA1DPTAFRHTR1DHTR2CADRA1B | |
| SCHEMBL23521232 | 0.94 | ADRA1D (0.77) | ADRA1DPTAFRHTR1DHTR2CADRA1B | |
| SCHEMBL23521233 | 0.94 | ADRA1D (0.77) | ADRA1DPTAFRHTR1DHTR2CADRA1B | |
| Platelet Activating Factor SCHEMBL14523316 | 0.94 | ADRA1D (0.77) | ADRA1DPTAFRHTR1DHTR2CADRA1B | |
| Platelet Activating Factor SCHEMBL12235513 | 0.94 | ADRA1D (0.77) | ADRA1DPTAFRHTR1DHTR2CADRA1B | |
| Platelet Activating Factor SCHEMBL2546758 | 0.94 | ADRA1D (0.77) | ADRA1DPTAFRHTR1DHTR2CADRA1B | |
| SCHEMBL26642894 | 0.94 | ADRA1D (0.77) | ADRA1DPTAFRHTR1DHTR2CADRA1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070077283-A1 | METHOD OF ENHANCING TRANSMUCOSAL DELIVERY OF THERAPEUTIC COMPOUNDS | NASTECH PHARMACEUTICAL COMPANY INC. | 2007-04-05 | — | — | US | claimed |
| US-20050032713-A1 | Platelet-activating factor antagonists as analgesic, anti-inflammatory, uterine contraction inhibiting, and anti-tumor agents | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2005-02-10 | — | — | US | claimed |
| US-20040028756-A1 | Platelet-activated factor antagonists as analgesic, anti-inflammatory, uterine contraction inhibiting, and anti-tumor agents | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2004-02-12 | — | — | US | claimed |
| WO-2016094226-A1 | PREVENTION AND TREATMENT OF INFLAMMATORY CONDITIONS | GLYCOREGIMMUNE, INC. (US) | 2016-06-16 | — | — | WO | disclosed |
| US-20160158258-A1 | PREVENTION AND TREATMENT OF INFLAMMATORY CONDITIONS | ALTIUM GROWTH FUND, LP | 2016-06-09 | — | — | US | disclosed |
| US-8394785-B2 | Methods for the treatment and amelioration of urticaria | JADO TECHNOLOGIES GMBH (DE) | 2013-03-12 | — | — | US | disclosed |
| US-8394785-B2 | Methods for the treatment and amelioration of urticaria | JADO TECHNOLOGIES GMBH (DE) | 2013-03-12 | — | — | US | disclosed |
| US-20110263531-A1 | METHODS FOR THE TREATMENT AND AMELIORATION OF ATOPIC DERMATITIS | JADO TECHNOLOGIES GMBH | 2011-10-27 | — | — | US | disclosed |
| US-20110263531-A1 | METHODS FOR THE TREATMENT AND AMELIORATION OF ATOPIC DERMATITIS | JADO TECHNOLOGIES GMBH | 2011-10-27 | — | — | US | disclosed |
| US-7998945-B2 | Methods for the treatment and amelioration of atopic dermatitis | JADO TECHNOLOGIES GMBH (DE) | 2011-08-16 | — | — | US | disclosed |
| US-7998945-B2 | Methods for the treatment and amelioration of atopic dermatitis | JADO TECHNOLOGIES GMBH (DE) | 2011-08-16 | — | — | US | disclosed |
| US-20070077283-A1 | METHOD OF ENHANCING TRANSMUCOSAL DELIVERY OF THERAPEUTIC COMPOUNDS | NASTECH PHARMACEUTICAL COMPANY INC. | 2007-04-05 | — | — | US | disclosed |
| US-20050032713-A1 | Platelet-activating factor antagonists as analgesic, anti-inflammatory, uterine contraction inhibiting, and anti-tumor agents | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2005-02-10 | — | — | US | disclosed |
| US-20040028756-A1 | Platelet-activated factor antagonists as analgesic, anti-inflammatory, uterine contraction inhibiting, and anti-tumor agents | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2004-02-12 | — | — | US | disclosed |
| US-20020142046-A1 | Protein particles for therapeutic and diagnostic use | YEN, RICHARD C.K. | 2002-10-03 | — | — | US | disclosed |
| US-5945033-A | ALBUMIN, HEMOGLOBIN MIXTURE; STABILITY | HEMOSPHERE, INC. (US) | 1999-08-31 | — | — | US | disclosed |
| US-5725804-A | ALBUMIN PARTICLES STABLE TO RESOLUBILIZATION, POLYOXYETHYLENE GLYCOL, ALCOHOL | HEMOSPHERE, INC. (US) | 1998-03-10 | — | — | US | disclosed |
| US-5726166-A | INOSITOL MONOPHOSPHATE OR A PHOSPHATIDYL INOSITOL | BRITISH TECHNOLOGY GROUP LIMITED (GB) | 1998-03-10 | — | — | US | disclosed |
| EP-0625911-B1 | MALARIA TREATMENTS | BRITISH TECH GROUP (GB) | 1997-04-09 | — | — | EP | disclosed |
| US-5616311-A | AQUEOUS ALBUMIN SUSPENSION STABILIZED BY HEMOGLOBIN PARTICLES | HEMOSPHERE, INC. (US) | 1997-04-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070077283-A1 | METHOD OF ENHANCING TRANSMUCOSAL DELIVERY OF THERAPEUTIC COMPOUNDS | PGF, PLAT, PTAFR | ADRA1D 1551/4885PTAFR 3/4885HTR1D 3160/4885 |
| US-20160158258-A1 | PREVENTION AND TREATMENT OF INFLAMMATORY CONDITIONS | RXRA, RXRG, CX3CR1 | ADRA1D 1168/4885PTAFR 1065/4885HTR1D 2288/4885 |
| US-20110263531-A1 | METHODS FOR THE TREATMENT AND AMELIORATION OF ATOPIC DERMATITIS | PHOSPHO1, SMPD3, SMPD1 | ADRA1D 875/4885PTAFR 819/4885HTR1D 917/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.